These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In vitro activity of daptomycin against isolates of Staphylococcus aureus and enterococci: first results from Turkey. Arslan H; Azap OK; Ergin F; Karaman SO; Oruç E Int J Antimicrob Agents; 2004 Jun; 23(6):642-3. PubMed ID: 15194140 [No Abstract] [Full Text] [Related]
3. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269 [TBL] [Abstract][Full Text] [Related]
4. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations. Brauers J; Kresken M; Menke A; Orland A; Weiher H; Morrissey I Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403 [TBL] [Abstract][Full Text] [Related]
5. 1,2,4-Oxadiazole antimicrobials act synergistically with daptomycin and display rapid kill kinetics against MDR Enterococcus faecium. Carter GP; Harjani JR; Li L; Pitcher NP; Nong Y; Riley TV; Williamson DA; Stinear TP; Baell JB; Howden BP J Antimicrob Chemother; 2018 Jun; 73(6):1562-1569. PubMed ID: 29518208 [TBL] [Abstract][Full Text] [Related]
6. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446 [TBL] [Abstract][Full Text] [Related]
7. Dodecyl sorbitan ethers as antimicrobials against Gram-positive bacteria. Belmessieri D; Gozlan C; Duclos MC; Dumitrescu O; Lina G; Redl A; Duguet N; Lemaire M Bioorg Med Chem Lett; 2017 Oct; 27(20):4660-4663. PubMed ID: 28917650 [TBL] [Abstract][Full Text] [Related]
8. New bisanthraquinone antibiotics and semi-synthetic derivatives with potent activity against clinical Staphylococcus aureus and Enterococcus faecium isolates. Socha AM; LaPlante KL; Rowley DC Bioorg Med Chem; 2006 Dec; 14(24):8446-54. PubMed ID: 16979896 [TBL] [Abstract][Full Text] [Related]
9. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010). Sader HS; Moet GJ; Farrell DJ; Jones RN Diagn Microbiol Infect Dis; 2011 Jul; 70(3):412-6. PubMed ID: 21546202 [TBL] [Abstract][Full Text] [Related]
10. Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci. Eliopoulos GM Eur J Clin Microbiol Infect Dis; 2005 Dec; 24(12):826-31. PubMed ID: 16315008 [TBL] [Abstract][Full Text] [Related]
11. Repurposing of the Tamoxifen Metabolites to Treat Methicillin-Resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococcus faecalis Infections. Miró-Canturri A; Vila-Domínguez A; Caretero-Ledesma M; Ayerbe-Algaba R; Pachón J; Jiménez-Mejías ME; Smani Y Microbiol Spectr; 2021 Oct; 9(2):e0040321. PubMed ID: 34668743 [TBL] [Abstract][Full Text] [Related]
12. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009. Dowzicky MJ Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154 [TBL] [Abstract][Full Text] [Related]
13. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). Sader HS; Watters AA; Fritsche TR; Jones RN BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104 [TBL] [Abstract][Full Text] [Related]
15. In vitro activities of antimicrobial cationic peptides; melittin and nisin, alone or in combination with antibiotics against Gram-positive bacteria. Dosler S; Gerceker AA J Chemother; 2012 Jun; 24(3):137-43. PubMed ID: 22759757 [TBL] [Abstract][Full Text] [Related]
16. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. Hall Snyder A; Werth BJ; Barber KE; Sakoulas G; Rybak MJ J Antimicrob Chemother; 2014 Aug; 69(8):2148-54. PubMed ID: 24777900 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to daptomycin in Enterococcus faecium. Montero CI; Stock F; Murray PR Antimicrob Agents Chemother; 2008 Mar; 52(3):1167-70. PubMed ID: 18180351 [TBL] [Abstract][Full Text] [Related]